IPO Listed — 17 Aug 2026
Listing Price: ₹980
Molbio Diagnostics IPO GMP History | Listing Price ₹980 & Kostak Rate
Molbio Diagnostics IPO has been listed on August 17, 2026 at a listing price of ₹980, against the issue price of ₹807 — a gain of ₹173 (+21.44%). The GMP peaked at ₹220 on 6 August 2026 and reached a low of ₹115 on 14 August 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Molbio Diagnostics IPO raised ₹939.7 Cr. through its IPO at a price band of ₹768 to ₹807 per share, with a lot size of 18 shares. The IPO was open for subscription from 10 Aug 2026 to 12 Aug 2026.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 17 Aug 2026 | ₹ 120 | 14.87% | ₹ 0 | ₹ 0 | |
| 16 Aug 2026 | ₹ 120 | 14.87% | ₹ 0 | ₹ 0 | |
| 15 Aug 2026 | ₹ 125 | 15.49% | ₹ 0 | ₹ 0 | |
| 14 Aug 2026 | ₹ 115 | 14.25% | ₹ 0 | ₹ 0 | |
| 13 Aug 2026 | ₹ 156 | 19.33% | ₹ 0 | ₹ 0 | |
| 12 Aug 2026 | ₹ 154 | 19.08% | ₹ 0 | ₹ 0 | |
| 11 Aug 2026 | ₹ 138 | 17.10% | ₹ 0 | ₹ 0 | |
| 10 Aug 2026 | ₹ 127 | 15.74% | ₹ 0 | ₹ 0 | |
| 09 Aug 2026 | ₹ 132 | 16.36% | ₹ 0 | ₹ 0 | |
| 08 Aug 2026 | ₹ 130 | 16.11% | ₹ 0 | ₹ 0 | |
| 07 Aug 2026 | ₹ 180 | 22.30% | ₹ 0 | ₹ 0 | |
| 06 Aug 2026 | ₹ 220 | 27.26% | ₹ 0 | ₹ 0 | |
| 05 Aug 2026 | ₹ 120 | 14.87% | ₹ 0 | ₹ 0 |
Molbio Diagnostics IPO Dates
| Event | Date |
|---|---|
| Open Date | 10 Aug, 2026 |
| Close Date | 12 Aug, 2026 |
| Allotment Date | 13 Aug, 2026 |
| Refund Date | 14 Aug, 2026 |
| Credit to Demat | 14 Aug, 2026 |
| Listing Date | 17 Aug, 2026 |
Molbio Diagnostics IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹807 |
| GMP-Based Estimate (Pre-Listing) | ₹927 (+14.9%) |
| Actual Listing Price | ₹980 (+21.44%) |
| Listing Gain / Loss | +₹173 per share |
| Listing Date | 17 Aug, 2026 |
Is Molbio Diagnostics IPO GMP Reliable?
Grey market premium for Molbio Diagnostics IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Molbio Diagnostics IPO full review for a fundamentals-based assessment before making any grey market trades.
Molbio Diagnostics IPO IPO Kostak Rate Explained
The Kostak rate for Molbio Diagnostics IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Molbio Diagnostics IPO
Its main product is the Truenat platform. This is a portable, battery-operated PCR based molecular testing system. It is made for places where lab facilities are limited, and it gives accurate results within an hour.
The company offers testing for more than 30 diseases through 43 diagnostic tests. These include tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV. Through its subsidiaries and tie-ups, it also provides radiology, digital pathology and breast health screening solutions. It keeps adding new products through its own R&D.
The company runs six manufacturing plants in India and serves customers in over 90 countries. Its customers include government health programmes, diagnostic labs, hospitals and international healthcare bodies.
It holds a good number of patents and global certifications, and has grown through some strategic acquisitions. As on 31 March 2026, the company had 1,225 permanent employees across R&D, manufacturing, quality, sales, finance and corporate functions.
Strengths & Risks
Strengths
- ✓ Truenat is its own patented platform. It is portable, runs on battery and gives PCR results in about an hour, which makes molecular testing possible in small towns and villages where full labs are not available.
- ✓ The product range is deep. It covers more than 30 diseases through 43 tests, including TB, HIV, Hepatitis B and C, and HPV.
- ✓ Reach is global. The company sells in more than 90 countries and runs six manufacturing plants in India.
- ✓ Growth has been strong. Total income went up from Rs 840.66 crore in FY2024 to Rs 1,455.17 crore in FY2026, and profit after tax almost doubled from Rs 83.54 crore to Rs 164.14 crore.
- ✓ Return ratios are healthy. RoCE was 20.98% and RoNW was 15.23%. EBITDA for FY2026 was Rs 328.24 crore.
- ✓ The fresh money goes into building the business. Rs 125.12 crore is for an R&D facility and a Centre of Excellence, and Rs 80.81 crore is for plant and machinery at Goa Unit I, Goa Unit II and the Visakhapatnam unit.
Risks
- ⚠ Most of the issue is an offer for sale. Out of Rs 939.70 crore, about Rs 739.70 crore is OFS. The company will get only around Rs 200 crore for its own growth.
- ⚠ The issue is priced high. At the upper band of Rs 807, the P/E is about 56.67 times on an EPS of Rs 14.24.
- ⚠ Borrowings have gone up sharply. Total borrowing rose from Rs 123.16 crore in FY2025 to Rs 412.64 crore in FY2026, more than three times in one year. None of the fresh issue money is set aside to repay this.
- ⚠ Promoter holding is low. It was 44.89% before the issue and will fall further to 41.29% after listing.
- ⚠ The company depends a lot on government health programmes, especially TB testing. A change in government tender policy, pricing or order size can hit revenue.
- ⚠ Profit is growing slower than sales. Revenue went up 42% but profit after tax rose 18% between FY2025 and FY2026.
- ⚠ Diagnostics is a heavily regulated business. The company needs approvals and certifications in every country it sells in, and any delay or loss of approval will affect sales.
- ⚠ The company competes with large global diagnostics players who have deeper pockets for research and marketing.
Frequently Asked Questions about Molbio Diagnostics IPO
What is the GMP of Molbio Diagnostics IPO?
The current Grey Market Premium (GMP) of Molbio Diagnostics IPO is ₹ 120.
What is the Kostak Price of Molbio Diagnostics IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Molbio Diagnostics IPO is currently not available.
What is the Subject to Sauda Price of Molbio Diagnostics IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Molbio Diagnostics IPO?
Molbio Diagnostics IPO listed on August 17, 2026 at ₹980, against the issue price of ₹807 — a gain of +21.44%.
How did the GMP of Molbio Diagnostics IPO trend before listing?
The GMP of Molbio Diagnostics IPO was stable in its final days before listing. The GMP peaked at ₹220 on 6 August 2026. View the day-wise table above for the complete GMP history.
Explore Molbio Diagnostics IPO Further
For a complete picture before making your investment decision, explore these resources:
